Meldonium

Meldonium (also known as Mildronate, THP, MET-88 or Quaterine) is a substance that optimize the energy metabolism in the heart during a lack of oxygen. The result is that the hart requires less oxygen and heart work a little easier under low oxygen (eg. Myocardial infarction and angina pectoris (angina)). Anti-Doping Agencies or Laboratories do not have enough data to state how the substance affects hearts on healthy persons - like young healthy athletes. A study shows that the anti-ischemic drug demonstrates an increase in endurance performance of athletes, improved rehabilitation after exercise, protection against stress, and enhanced activations of central nervous system (CNS) functions. These are the effects that one could take advantage of in sport, so this drug is likely to be highly sought after as a dopant in accordance with this. One could not ignore the fact that it may also have muscle-building effects. The drug can thus have different mechanisms of the effect on mitochondria and modulating metabolism in the heart is one of these, but here it's probably a lot that is still relatively unknown. It was on the monitoring list of WADA in 2015, and was moved to the Prohibited list in 2016. as there were strong indications relatively widespread use in sport (based on laboratory and analysis data from different WADA-accredited laboratories, especially in endurance and strength sports. Meldonium is currently manufactured and marketed by Grindeks, a pharmaceutical company based in Latvia. It is used in Lithuania and the Russian Federation. It has not been approved by the Food and Drug Administration for use in the United States. The brand name in your country can be found here: http://www.drugs.com/international/meldonium.html Sources: Antidoping Norway, WADA, Wikipedia, Drugs.com, Wiley Online Library (http://onlinelibrary.wiley.com/doi/10.1002/dta.1788/full)